CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy
- PMID: 35260306
- DOI: 10.1016/j.numecd.2022.01.026
CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy
Abstract
Background and aims: The prevalence of type 2 diabetes (T2D) in Italy is increasing and cardiovascular disease (CVD) represents the leading cause of death in this population. CAPTURE was a multinational, multicentre, non-interventional, cross-sectional study assessing the prevalence of CVD, atherosclerotic CVD (AsCVD) and CVD subtypes among patients with T2D, across 13 countries. Here we report the results from Italy.
Methods and results: Overall, 816 patients with T2D (median age, 69 years [interquartile range: 62-75]; median duration of diabetes, 11.2 years [interquartile range: 5.7-18.7]) were recruited during routine clinical visits at secondary care centres in Italy between December 2018-September 2019. The prevalence of CVD was estimated at 38.8%, largely accounted for by AsCVD (33.1%). The most prevalent CVD subtype was coronary heart disease (20.8%), followed by carotid artery disease (13.2%). Most patients (85.9%) were prescribed oral glucose-lowering agents (GLAs), particularly biguanide (76.7%). Insulin use was higher in patients with CVD (41.3%) than in patients without CVD (32.9%). Sodium-glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were prescribed to 20.2% vs 14.6%, and 14.5% vs 16.6% of patients with CVD compared to those without CVD, respectively.
Conclusion: The results show that, in Italy, more than one in three patients with T2D attending secondary care centres have CVD, 85% of whom have AsCVD, yet only a minority are treated with SGLT2is and GLP-1 RAs, in discordance with the recommendations of current national and international guidelines.
Keywords: Cardiovascular disease; Cross-sectional study; Italy; Prevalence; Type 2 diabetes.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest GTR: Speakers’ bureau honoraria from and advisory board membership for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi and Mundipharma. GC: No conflicts of interest to declare. FA: Speakers’ fees from Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Mundipharm and Sanofi, and consultant fees from Boehringer Ingelheim and Eli Lilly. MGC: Advisory board/speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. CB: Novo Nordisk employee and shareholder. EM: Speaking and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi; institutional research grants from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, Molteni and Novo Nordisk.
Similar articles
-
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.Cardiovasc Diabetol. 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0. Cardiovasc Diabetol. 2021. PMID: 34315481 Free PMC article.
-
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.Diabetes Ther. 2022 Dec;13(11-12):1921-1932. doi: 10.1007/s13300-022-01320-1. Epub 2022 Sep 21. Diabetes Ther. 2022. PMID: 36131064 Free PMC article.
-
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study.Cardiovasc Diabetol. 2022 Oct 8;21(1):203. doi: 10.1186/s12933-022-01631-4. Cardiovasc Diabetol. 2022. PMID: 36209118 Free PMC article.
-
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.Cardiovasc Diabetol. 2022 Aug 4;21(1):144. doi: 10.1186/s12933-022-01575-9. Cardiovasc Diabetol. 2022. PMID: 35927730 Free PMC article. Review.
-
Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):61-72. doi: 10.1111/jcpt.13226. J Clin Pharm Ther. 2020. PMID: 32910492 Free PMC article. Review.
Cited by
-
Genetic, lifestyle and metabolic factors contributing to cardiovascular disease in the Italian population: a literature review.Front Nutr. 2024 Apr 4;11:1379785. doi: 10.3389/fnut.2024.1379785. eCollection 2024. Front Nutr. 2024. PMID: 38638292 Free PMC article. Review.
-
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice.Int J Mol Sci. 2023 Apr 30;24(9):8099. doi: 10.3390/ijms24098099. Int J Mol Sci. 2023. PMID: 37175805 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical